Andres Poveda, MD

Articles

Andres Poveda, MD, on the Implications of the Phase 3 SOLO2/ENGOT-ov21 Trial

July 13th 2020

The expert in ovarian cancer indicated that treatment with the studied maintenance olaparib tablets could aid patients in having a more regular lifestyle.

Phase 3 SOLO2/ENGOT-ov21 Trial Shows Promise for Maintenance Olaparib in Ovarian Cancer

Andres Poveda, MD

June 29th 2020

The results of the trial demonstrated that maintenance olaparib provided an unprecedented improvement in median OS versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Andres Poveda, MD, on the Phase III SOLO2/ENGOT-ov21 Final OS Data in Ovarian Cancer

Andres Poveda, MD

June 4th 2020

Final overall survival results from the trial showed that maintenance olaparib provided an unprecedented improvement in median overall survival versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.